Entering text into the input field will update the search result below

IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript

May 05, 2021 3:12 PM ETIVERIC bio, Inc. (ISEE) Stock
SA Transcripts profile picture
SA Transcripts

IVERIC bio, Inc. (NASDAQ:ISEE) Q1 2021 Earnings Conference Call May 5, 2021 8:00 AM ET

Company Participants

Kathy Galante - Senior Vice President-Investor Relations

Glenn Sblendorio - Chief Executive Officer

Keith Westby - Chief Operating Officer

Pravin Dugel - President

David Carroll - Chief Financial Officer

Conference Call Participants

Tiago Fauth - Credit Suisse

Stacy Ku - Cowen

David Nierengarten - Wedbush Securities


Good morning and welcome to the IVERIC bio First Quarter 2021 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. Please note this call is being recorded.

I would now like to turn the conference over to Kathy Galante, Senior Vice President, Investor Relations. Please go ahead.

Kathy Galante

Good morning, and welcome to IVERIC bio's conference call. Representing IVERIC bio today are Glenn Sblendorio, Chief Executive Officer; Pravin Dugel, President; David Carroll, Chief Financial Officer; Dhaval Desai, Chief Development Officer; Abraham Scaria, Chief Scientific Officer; and Keith Westby, Chief Operating Officer

I would like to remind you that today we will be making statements relating to IVERIC bio's future expectations regarding operational, financial and research and development matters, including statements regarding our expectation for patient enrollment and patient retention in GATHER2, our second Phase 3 clinical trial evaluating Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration; our expectations to use GATHER1, our previously announced clinical trial of Zimura for the treatment of GA secondary to AMD as a Phase 3 clinical trial; our development and regulatory strategy for Zimura; and our other product candidates, including our expectations for additional indications for which we may pursue the development of Zimura and IC-500, our hypothesis regarding complement inhibition and HtrA1 inhibition as mechanism of action for the treatment of GA and potentially other stages of AMD; our projected use

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

More on ISEE

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.